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doi:10.1016/j.ejvs.2011.08.014Abstract Objective: To assess the clinical importance of on-treatment function testing of
platelets in patients on aspirin after catheter-based vascular interventions.
Materials and methods: In 109 patients with symptomatic peripheral arterial disease (PAD) of
the lower limbs, platelet function testing (adenosine diphosphate-, collagen- and epinephrine-
induced aggregation using light transmission aggregometry) was performed before and at
multiple time points up to 1 year after a percutaneous angioplasty. Using univariate mixture
models and BoxeCox transformation to ensure normally distributed individual variances, we
investigated if an intraindividual variability exists and if it has a consequence for clinical
outcome.
Results: Response to aspirin as measured by platelet aggregometry varies considerably over
time in most patients. However, the intraindividual variance over time was not significantly
correlated either with restenosis/reocclusion after 1 year or with adverse long-term outcome
(occurrence of death for cardiovascular cause, stroke or myocardial infarction in up to 8 years
follow-up).
Conclusions: Response to aspirin does not seem to have a role in determining long-term
outcome in patients with symptomatic PAD. The fact that testing of platelet function at only
one time point has reduced significance may have implications for all clinical settings in which
aspirin is used for the prevention of thrombo-embolic events.
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810 B. van der Loo et al.Aspirin (acetylsalicylic acid; ASA) is one of the most
important drugs used for the prevention of thrombo-
embolic vascular events. A highly variable interindividual
platelet response to the treatment with aspirin has been
reported.1 ‘Aspirin resistance’ is defined differently by
different groups. Clinically, ‘aspirin resistance’ or hypo-
responsiveness occurs in patients who, although being on
therapeutic doses of aspirin, develop thrombo-embolic
cardiovascular events.2 Others, however, have supported
not including “thrombo-embolic events while on aspirin” as
a clinical definition for aspirin resistance as only about one-
fourth of all vascular complications can be prevented by
any one pharmacological therapy alone.3
Biochemical assessment of platelet function may detect
hypo- or non-response of platelets to aspirin therapy.
However, to date, it is not clear which of several available
laboratory methods has the best reliability and, in partic-
ular, the highest predictability for clinical events.4 A recent
meta-analysis of 20 studies using different aggregation
tests to assess individual platelet response to aspirin
demonstrated an elevated cardiovascular risk associated
with aspirin resistance.5 Therefore, although the clinical
importance of non-responsiveness is not yet fully under-
stood, there is evidence for its clinical relevance.
Furthermore, in patients with cerebrovascular ischaemic
events being on aspirin for secondary stroke prophylaxis,
non-responsiveness was significantly associated with
recurrent ischaemia.6
Peripheral arterial disease (PAD), in particular of the
lower limbs, is highly prevalent especially in the elderly
population.7 Its utmost importance as a marker of athero-
sclerotic vascular disease in general has been confirmed.8
Percutaneous transluminal angioplasty (PTA) to revas-
cularise peripheral arteries is an established treatment in
symptomatic patients. Aspirin is given routinely to patients
being treated for PAD and has been shown to reduce the
risk of reocclusion after vascular procedures.9 Therefore,
response to aspirin in this setting is of great importance.
A previous study analysing the time course of agonist-
induced platelet aggregation in patients who underwent
PTA of the lower limbs provided inconclusive results and
was only limited to a 12-month follow-up.10
Here, we wanted to investigate if, apart from the known
variable interindividual platelet response to aspirin, an
intraindividual variability also exists, and, if so, whether
such an intraindividual variance has a consequence for
clinical outcome. To this end, individual variances were
correlated first with the occurrence of restenosis/reocclu-
sion in patients after PTA of the lower limbs within 1 year.
Second, we tested the hypothesis that defined clinical end
points (e.g., cardiovascular events such as myocardial
infarction, stroke and peripheral re-intervention) during
long-term follow-up of up to almost 8 years are more often
reached in patients with a high variance.
Materials and Methods
Patients
The current study was done as a substudy of a previously
published trial.11 Over a 3-year-period (January 1999 untilDecember 2001) 109 of 250 patients screened with symp-
tomatic (Fontaine clinical stage IIeIV) PAD of the lower
limbs, scheduled to undergo PTA at the Clinic of Angiology,
University Hospital Zurich, were enrolled. The study was
approved by the local ethics committee and performed
according to the Declaration of Helsinki. All patients gave
their written informed consent. Age, sex, cardiovascular
risk factors, history and current medication were recorded
at baseline. Characteristics of the lesions were recorded
and classified according to the TransAtlantic interSocietal
Consensus (TASC) classification.12 Basic treatment was 100-
mg aspirin daily, which was initiated the day before the
procedure if the patient was not already on aspirin (which
was the case in all but two patients). Adjunctive drug
therapy during the intervention (unfractionated or low-
molecular-weight heparin) was at the operator’s discre-
tion. Patients were excluded if they were taking anticoag-
ulants at the time of admission, had an intolerance to
aspirin, active bleeding or haemorrhagic diathesis. Patients
receiving non-steroidal anti-inflammatory agents (NSAIDs)
were also excluded. Furthermore, patients with renal
failure, uncontrolled arterial hypertension, recent surgery
of the central nervous system, nonatherosclerotic vascular
disease, lesions in femoropopliteal bypass grafts, stent
implantation and stroke were also excluded. At time of
admission, routine laboratory tests (complete blood cell
count, haematocrit, serum creatinine, international nor-
malised ratio (INR), cholesterol and triglycerides) were
performed using standard methods.
Mean follow-up was 80 months (range 52e94 months).
Owing to the parallel group design of the original trial,11
patients had initially been randomised to one of two
treatment arms (no additional treatment vs. dalteparin,
5000 IU subcutaneously once daily on day 1 and 2 after the
intervention followed by 2500 IU once daily for 90 days in
addition to aspirin 100 mg daily). Unpaired t-test revealed
that, after 3 months, neither for adenosine diphosphate
(ADP) (pZ 0.4942, ns) nor for epinephrine (pZ 0.9594, ns)
or collagen (pZ 0.5541, ns) any significance of an influence
of dalteparin on parameters of platelet aggregation could
be observed. Therefore, patients who had received dalte-
parin within the first 3 months after angioplasty were also
included into the current study.Follow-up and end points
ADP-, collagen- and epinephrine-induced platelet aggre-
gation was assessed before, and at 1, 3, 6 and 12 months
after the percutaneous procedure. Patients were followed
up for 80 months (range 52e94 months). The day after the
procedure as well as at 1, 3, 6 and 12 months after PTA all
patients were examined clinically, and pulse volume
recordings, determination of ankle-brachial index (ABI), as
well as colour-coded duplex sonography were performed.
Furthermore, drug use, in particular NSAID and/or the
addition of a thienopyridine, was monitored at the time of
outpatient testing. Testing of platelet function was always
performed under fasting conditions at the same time of the
day (early in the morning). Long-term follow-up was based
on patient chart review in the majority of the cases. If this
was not available, a telephone interview was performed.
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restenosis/reocclusion in the dilated segment within 1 year
and the secondary (combined) end point consisting of one
or more of the following clinical end points during long-
term follow-up: occurrence of a non-fatal cardiovascular
event (myocardial infarction or stroke); death for cardio-
vascular cause; need for an invasive (either surgically or
catheter-based) vascular intervention in any peripheral
artery; and worsening of clinical symptoms as documented
by a drop in ABI of >0.1.Testing of platelet function
ADP-, collagen- and epinephrine-induced platelet aggre-
gation were assessed by light transmittance aggregometry
(LTA). In the fasting and resting patient, blood was taken
from an antecubital vein via i.v. cannula (1.2 mm) directly
into silicon-coated vacutainer tubes containing 0.5-ml
buffered sodium citrate (3.8%). Samples were processed
immediately, and platelet aggregation was measured after
centrifugation (100 G, 10 min, room temperature (RT)) of
citrated blood (3.8%; 1:10) to get platelet-rich plasma
(PRP). In addition, the remaining sample was further
centrifuged at a higher rate (3000 G, 15 min, RT) to obtain
platelet pure plasma (PPP). To determine platelet aggre-
gation to the different agonists, a standardised plasma
sample with a total platelet count of 250 G l1 was used by
adjusting PRP with PPP. Platelets were stimulated with
epinephrine (final concentration 0.1 mmol l1), collagen
(final concentration 5 mgl1) and ADP (final concentration
0.002 moll1), and aggregation was measured using an
APACT 4 aggregometer (Ahrensburg, Germany). Aggregation
was expressed as the maximum percentage change in light
transmittance from baseline.
The coefficient of variation (CV) for LTA in our labora-
tory was 8.9% (n Z 20).Statistical analysis
For data management and analysis, the statistical software
package R, version 2.6.1 (R Development Core Team,
Vienna, Austria) was used. Continuous variables are repor-
ted as means  standard deviation (SD) and categorical
variables as counts and percentages. Pearson’s correlation
was used to check if two continuous variables were strongly
correlated, so that they could be treated as exchangeable.
The ManneWhitney U test was used for comparisons of
continuous variables and the chi-squared test for compar-
isons of categorical variables. A p-value <0.05 was
considered to be statistically significant.
Univariate mixture models
For each time point and each of the three measures (ADP,
collagen, and epinephrine), we first fit three different
univariate models: one using the ordinary normal distribu-
tion, one using a mixture of two normal distributions with
equal variances and one using a mixture of two completely
distinct normal distributions. The different models were
calculated using an expectation-maximisation (EM) algo-
rithm. They were compared graphically and via the Akaike’sinformation criterion (AIC). The model with the smallest
AIC for each time point has been selected.
BoxeCox transformation
To compare variances of ADP-, collagen- or epinephrine-
induced platelet aggregation over time between patients
with and without restenosis and between patients reaching
one of the end points and those who did not, a t-test can only
be performed if these variances are approximately normally
distributed in both groups. As this was not the case, we used
the BoxeCox transformation to achieve normality. We
decided to use the quartic root (i.e., the squareroot of the
SD) of the variances of ADP, collagen and epinephrine.
Furthermore, in order to appropriately incorporate the fact
of variable numbers ofmeasurements in different individuals
into the analyses, a weighted t-test was used. To avoid the
problem ofmultiple testing, Bonferroni correctionwas used.Results
Baseline demographic and clinical characteristics as well as
laboratory variables are shown in Table 1A and B.
Patients were grouped according to the occurrence of
restenosis/reocclusion within 12 months (Table 1A) as the
primary end point and according to the occurrence of any
fatal or non-fatal cardiovascular event and/or the need for
any surgically or catheter-based vascular intervention (i.e.,
secondary end point) during complete long-term follow-up
(Table 1B). As expected, patients with restenosis/reocclu-
sion had a lower ABI than those without restenosis/reoc-
clusion within the first year (0.64  0.7 vs. 0.74  0.19;
p Z 0.0077) (Table 1A). Patients reaching the combined
end point were slightly younger than those who did not
(68  11 years vs. 72  10 years; p Z 0.046) (Table 1B).
Apart from these differences, the groups were similar with
respect to their baseline parameters.
Mean values of ADP-, epinephrine- and collagen-induced
platelet aggregation, as assessed by LTA, for all patients up
to 1 year after the initial percutaneous procedure are
shown in Table 2.
When comparing these values between patients with any
event and those without during long-term follow-up, no
significant differences could be detected.
Only 25.6% of the patients were sampled at 12 months,
and 52% of all patients had their agonist-induced platelet
aggregation measured at 3 time points (Table 2).
However, in order to circumvent this problem, and to
analyse individual variances in the best possible way under
these circumstances, a weighted t-test was performed.
We then wanted to investigate if subgroups exist, that is,
patients whose values for platelet aggregation upon stim-
ulation are at all time points higher or lower than the
average. To this end, we first plotted all data separately for
each individual (Fig. 1).
There was a considerable amount of variation in most of
the individuals. As outlined above, we therefore tried to fit
mixture distributions in the univariate (i.e., for all timepoints
separately) case. For each time point, we chose for ADP
(epinephrine and collagen not shown) the best out of three
possible univariate models (normal distribution; mixture of
two normal distributions with equal variances; andmixture of
Table 1 Baseline demographic and clinical characteristics of all patients by end points.
A
restenosis/reocclusion (n Z 48) no restenosis/reocclusion (n Z 61) p
Age (years) 68  11.3 70  10.2 0.377
Male 25 (52%) 36 (59%) 0.353
Diabetes 16 (33%) 18 (30%) 0.755
Hypercholesterolaemia 35 (73%) 41 (67%) 0.565
Arterial hypertension 37 (77%) 50 (82%) 0.439
Pack years 32.98  29.1 34.33  40.0 0.848
History of coronary heart disease 16 (33%) 26 (43%) 0.258
History of cerebrovascular disease 8 (17%) 6 (10%) 0.322
TASC classification 0.207
A 9 (19%) 12 (20%)
B 10 (21%) 22 (36%)
C 21 (44%) 22 (36%)
D 8 (17%) 5 (8%)
Ankle-brachial index 0.64  0.17 0.74  0.19 0.0077
Platelet count (103/ml) 256  73 265  75 0.544
Fibrinogen (mg/dl) 396  97 381  79 0.401
B
with events* (n Z 66) without events* (n Z 43) p
Age (years) 68.1  11.4 72.3  9.7 0.046
Male 37 (56%) 24 (56%) 0.979
Diabetes 23 (35%) 11 (26%) 0.307
Hypercholesterolaemia 50 (76%) 27 (63%) 0.146
Arterial hypertension 51 (77%) 37 (86%) 0.256
Pack years 36.4  38.8 27.9  28.2 0.234
History of coronary heart disease 24 (36%) 18 (42%) 0.564
History of cerebrovascular disease 11 (1.5%) 3 (7%) 0.139
TASC classification 0.722
A 11 (17%) 10 (23%)
B 19 (29%) 13 (30%)
C 26 (39%) 16 (37%)
D 10 (15%) 4 (9%)
Ankle-brachial index 0.68  0.19 0.71  0.19 0.514
Platelet count (103/ml) 270  78 249  66 0.156
Fibrinogen (mg/dl) 392  94 386  80 0.740
Bold indicates statistic significance.
*events Z clinical end points (myocardial infarction, stroke, peripheral re-intervention at any site; death for cardiovascular cause).
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distributions with distinct variances was chosen for time
points 0 and 12. A mixture of two normal distributions with
equal variancewas chosen for timepoints 3 and 6.Onenormal
distribution was chosen for time point 1 (Fig. 2).
We found that there was no distinct subgroup detectable
whichwould remain the sameover the observed time period.
We also calculated correlations of the agonists ADP,
epinephrine and collagen for all five time points. Although
there was a positive correlation remaining relatively
constant over time, this correlation is not strong (between
r Z 0.25 and r Z 0.64). Therefore, we did not treat the
agonists as exchangeable.
We then wanted to analyse whether the initially
observed high variance of ADP-, epinephrine- and collagen-
induced platelet aggregation within any individual patient
might have a significant influence on the occurrence of
restenosis/reocclusion (within 1 year after PTA) and/or thecombined end point (during complete long-term follow-up).
Results of a weighted t-test are shown in Table 3.
In all but one constellation there was no evidence for
a difference between the groups. Only for the time course of
collagen, a p-value below 0.05 indicated a significant differ-
ence with respect to the occurrence of restenosis/reocclu-
sion. However, in this context, the multiple testing problem
has to be borne in mind, so that the probability of a wrong
significant result cannot be controlled via aZ 0.05 anymore.
The appropriate level of significance resulting from the Bon-
ferroni correction is 0.008. Therefore, no evidence for
a difference between the groups could be found.Discussion
In our study with its unique aspects of multiple time points
of platelet function testing and a very long clinical follow-
Table 2 ADP-, epinephrine- and collagen-induced platelet aggregation according to the secondary end point in PAD patients
(n Z 109) on aspirin before and during a follow-up period of twelve months after PTA.
with events* (n Z 66) without events* (n Z 43) p
ADP
Baseline (n Z 109) 35.2  15.1 34.6  15.0 0.839
1 month (n Z 57) 32.4  12.7 33.5  15.4 0.777
3 months (n Z 39) 31.7  14.4 31.9  17.1 0.964
6 months (n Z 28) 38.2  19.6 35.7  9.4 0.716
12 months (n Z 28) 35.9  11.9 32.6  12.0 0.480
Epinephrine
Baseline (n Z 108) 42.1  18.5 43.6  20.3 0.701
1 month (n Z 57) 41.0  20.6 41.8  16.5 0.879
3 months (n Z 38) 40.0  18.8 34.7  18.3 0.382
6 months (n Z 28) 41.2  19.3 41.6  14.9 0.963
12 months (n Z 24) 43.0  24.1 34.8  13.4 0.342
Collagen
Baseline (n Z 108) 45.0  20.4 48.8  21.2 0.357
1 month (n Z 55) 45.6  18.3 52.8  18.7 0.176
3 months (n Z 38) 50.3  13.9 42.5  15.0 0.103
6 months (n Z 28) 50.3  21.9 48.2  16.6 0.802
12 months (n Z 22) 48.3  24.6 48.0  21.3 0.976
*events Z clinical end points (myocardial infarction, stroke, peripheral re-intervention at any site; death for cardiovascular cause).
Values are means  SD, in %.
Response to Aspirin and Peripheral Arterial Disease 813up, we found that platelet aggregation results using light
transmission aggregometry in symptomatic patients with
PAD intraindividually vary considerably over time and do
not correlate with long-term outcome. To the best of our
knowledge, this is the first study to describe this. Others
have recently reported a high intraindividual variability of
ADP- and collagen-induced platelet aggregation.13
However, these findings were observed in healthy individ-
uals receiving aspirin for up to 8 weeks only, whereas we
describe this for the first time in a pathophysiologic
context. Furthermore, we had multiple time points for
platelet function testing during a long period of 12 months
and correlated our findings with clinical end points during
a follow-up of up to 8 years.
Because of the missing values, especially for the later
time points, it was difficult to fit complex mixture distri-
butions. However, we could circumvent this problem byFigure 1 Platelet aggregation to ADP, collagen and epinephrin
(n Z 109). There are variable numbers of measurements per indivusing a weighted t-test. We cannot rule out that variable
numbers of measurements in different individuals might
possibly have affected our data on the correlation between
intraindividual variance and long-term cardiovascular
outcome. However, our main conclusion (i.e., that testing
of platelet function at one time point only has reduced
significance) remains unaffected.
This finding may potentially entail serious implications, as
it means that on-treatment function testing of aspirin, done
at one time point, usually before a peripheral or coronary
intervention in certain patients at individually high risk for
thrombosis, has a reduced significance, at least when LTA is
used. This could also mean that a correlation between
response to aspirin and clinical events (as shown in several
studies in the past) has to be interpreted with caution.
Low-dose daily aspirin is a widely accepted strategy for
secondary prevention in patients with vascular disease. It ise separately for each individual at five different time points
idual.
814 B. van der Loo et al.still a matter of controversy if the biochemical detection of
hypo- or non-responsiveness to aspirin has a clinical
meaning, that is, an association with thrombotic events.
However, in our study, we could not show that the indi-
vidually high variance translates into a higher risk for
restenosis/reocclusion after PTA or for the occurrence of
a major cardiovascular event.
We further found no obvious hint for the existence of
subgroups of patients in which platelet aggregation testing
revealed a lack of response to aspirin at all time points.
With univariate mixture models fit to find the correct
location for each individual within the mixture clearly
separated patients could not be identified.
An interesting hypothesis that arises from our work is
that a single patient being a responder to aspirin once will
not always be a responder.Figure 2 Distribution of values for ADP-induced platelet aggreg
months of follow-up. For each time point, the best of three possi
distributions; mixture of two normal distributions with equal varian
a detailed description see Methods.In this context, the different aetiologies for ‘aspirin
resistance’ have to be borne in mind.
One of the most important reasons for ‘aspirin resis-
tance’ is a lack of compliance.14,15 However, virtually all
our patients had been on aspirin at the beginning of the
study. The variation in platelet response to agonists as
depicted in Fig. 1 would imply a high degree of irregularity
in taking aspirin which makes this explanation completely
speculative. In a previous study, platelet hyporesponsive-
ness to aspirin was evaluated in 24 patients at day 10 and 1
month after coronary artery bypass graft surgery.16 The
authors found that although most patients could be classi-
fied as ‘aspirin-resistant’ shortly after their operation,
responsiveness to aspirin was restored in a majority of the
patients at 1-month follow-up.16 We used in the present
work a completely different study design in a differentation over time. 0 indicates baseline, 1, 3, 6, and 12 indicate
ble fitting models (mixture of two completely distinct normal
ces; model with just one normal distribution) was chosen. For
Table 3 Point estimates, confidence intervals and p-values for a weighted t-test for differences of the quartic root of the
variances for ADP-, epinephrine- and collagen-induced platelet aggregation. Restenosis indicates restenosis/reocclusion of the
dilated segment within one year, event indicates the secondary (Zcombined) end point during long-term follow-up.
Point estimate Lower limit Upper limit p
ADP, restenosis/reocclusion 0.087 0.632 0.458 0.751
ADP, event* 0.011 0.520 0.542 0.967
COLL, restenosis/reocclusion 0.551 1.035 0.067 0.026
COLL, event* 0.116 0.613 0.380 0.643
EPI, restenosis/reocclusion 0.129 0.365 0.622 0.605
EPI, event* 0.411 0.067 0.889 0.091
*event Z clinical end points (myocardial infarction, stroke, peripheral re-intervention at any site; death for cardiovascular cause).
Response to Aspirin and Peripheral Arterial Disease 815group of patients. Furthermore, we here describe a high
degree of individual variance in the platelet responsiveness
to aspirin rather than a restoration of platelet function.
However, our data also point to a transient nature of
response to aspirin, implying its modifiability.
In this study, we did not aim to identify possible modu-
lating factors nor to tackle the question whether a defec-
tive action of aspirin on the arachidonic acid pathway,
insufficient bioavailability, inadequate, that is, too low
dosage, or a progression of PAD is causally involved.17,18
However, none of the aforementioned causes could really
explain the phenomenon described here.
Platelet alterations have previously been described in
patients with PAD.19 Thus, it is conceivable that plate-
leteplaque interaction and/or platelet-injured endothelial
cell interaction may modulate platelet function to a vari-
able degree, depending on the actual state of disease,
influenced by inflammatory processes.
Strong evidence linking ‘aspirin resistance’ assayed
ex vivo and the future risk ofmyocardial infarction, stroke or
cardiovascular death came from a nested case-control study
on a subgroup of patients enrolled in the heart outcomes
prevention evaluation (HOPE) study.20 In the current study, it
was not our principal aim to merely correlate response to
aspirin with clinical long-term outcome.
Interestingly, in a previous reproducibility study specif-
ically designed to measure platelet aggregation over time,
very consistent results were found in a small proportion of
individuals exhibiting an unusual hyperreactivity to
agonists.21 However, this study had been performed in
healthy volunteers not being on aspirin.
Our results cast doubt on the significance of platelet
function testing using LTA in patients while being on aspirin
when assessed at one time point only. Our data may imply
that the modalities of such tests will have to be refined in
the future.Conflict of Interest
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